Effect of Human Wharton's Jelly Mesenchymal Stem Cell Paracrine Signaling on Keloid Fibroblasts

Overview

Journal Stem Cells Transl Med

Publisher Oxford University Press

Specialties Cell Biology
Pharmacology

Date 2014 Jan 18

PMID 24436441

Citations 35

Authors

Anna I Arno

Saeid Amini-Nik

Patrick H Blit

Mohammed Al-Shehab

Cassandra Belo

Elaine Herer

Marc G Jeschke

Affiliations

Soon will be listed here.

Abstract

Keloid scars are abnormal benign fibroproliferative tumors with high recurrence rates and no current efficacious treatment. Accumulating evidence suggests that human umbilical cord Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) have antifibrotic properties. Paracrine signaling is considered one of the main underlying mechanisms behind the therapeutic effects of mesenchymal stem cells. However, the paracrine signaling effects of WJ-MSCs on keloids have not yet been reported. The aim of this study is to investigate paracrine signaling effects of human WJ-MSCs on keloid fibroblasts in vitro. Human umbilical cords and keloid skin samples were obtained, and WJ-MSCs and keloid fibroblasts were isolated and cultured. One-way and two-way paracrine culture systems between both cell types were investigated. Plasminogen activator inhibitor-I and transforming growth factor-β2 (TGF-β2) transcripts were upregulated in keloid fibroblasts cultured with WJ-MSC-conditioned medium (WJ-MSC-CM) and cocultured with inserts, while showing lower TGF-β3 gene expression. Interleukin (IL)-6, IL-8, TGF-β1, and TGF-β2 protein expression was also enhanced. The WJ-MSC-CM-treated keloid fibroblasts showed higher proliferation rates than their control keloid fibroblasts with no significant change in apoptosis rate or migration ability. In our culture conditions, the indirect application of WJ-MSCs on keloid fibroblasts may enhance their profibrotic phenotype.

Citing Articles

Wharton's jelly stem cells delivered via a curcumin-loaded nanofibrous wound dressings improved diabetic wound healing via upregulating VEGF and IGF genes: An in vitro and in vivo study.

Chen C, Zhao H, Zhang W, Hong X, Li S, Rohani S Regen Ther. 2024; 26:547-556.

PMID: 39210999 PMC: 11359744. DOI: 10.1016/j.reth.2024.06.018.

Stem cell-based therapy for fibrotic diseases: mechanisms and pathways.

Taherian M, Bayati P, Mojtabavi N Stem Cell Res Ther. 2024; 15(1):170.

PMID: 38886859 PMC: 11184790. DOI: 10.1186/s13287-024-03782-5.

Therapeutic role of exosomes and conditioned medium in keloid and hypertrophic scar and possible mechanisms.

Zhong Y, Zhang Y, Yu A, Zhang Z, Deng Z, Xiong K Front Physiol. 2023; 14:1247734.

PMID: 37781228 PMC: 10536244. DOI: 10.3389/fphys.2023.1247734.

An updated review of the immunological mechanisms of keloid scars.

Lee C, Tsai C, Chen C, Yeh Y, Chung W, Chen C Front Immunol. 2023; 14:1117630.

PMID: 37033989 PMC: 10075205. DOI: 10.3389/fimmu.2023.1117630.

Advances in the pathogenesis and clinical application prospects of tumor biomolecules in keloid.

Xia Y, Wang Y, Shan M, Hao Y, Liu H, Chen Q Burns Trauma. 2022; 10:tkac025.

PMID: 35769828 PMC: 9233200. DOI: 10.1093/burnst/tkac025.

References

Reinders M, Rabelink T, De Fijter J . The role of mesenchymal stromal cells in chronic transplant rejection after solid organ transplantation. Curr Opin Organ Transplant. 2012; 18(1):44-50. DOI: 10.1097/MOT.0b013e32835c2939. View

Gauglitz G, Korting H, Pavicic T, Ruzicka T, Jeschke M . Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med. 2010; 17(1-2):113-25. PMC: 3022978. DOI: 10.2119/molmed.2009.00153. View

Moulin V, Larochelle S, Langlois C, Thibault I, Lopez-Valle C, Roy M . Normal skin wound and hypertrophic scar myofibroblasts have differential responses to apoptotic inductors. J Cell Physiol. 2004; 198(3):350-8. DOI: 10.1002/jcp.10415. View

Adzick N, Lorenz H . Cells, matrix, growth factors, and the surgeon. The biology of scarless fetal wound repair. Ann Surg. 1994; 220(1):10-8. PMC: 1234281. DOI: 10.1097/00000658-199407000-00003. View

Ghosh A, Vaughan D . PAI-1 in tissue fibrosis. J Cell Physiol. 2011; 227(2):493-507. PMC: 3204398. DOI: 10.1002/jcp.22783. View

Zhao Y, Li T, Wei X, Bianchi G, Hu J, Sanchez P . Mesenchymal stem cell transplantation improves regional cardiac remodeling following ovine infarction. Stem Cells Transl Med. 2012; 1(9):685-95. PMC: 3659738. DOI: 10.5966/sctm.2012-0027. View

Lin H, Zhang Z, Shi M, Xu R, Fu J, Geng H . [Prospective controlled trial of safety of human umbilical cord derived-mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis]. Zhonghua Gan Zang Bing Za Zhi. 2012; 20(7):487-91. DOI: 10.3760/cma.j.issn.1007-3418.2012.07.002. View

Lee M, Jung J, Na K, Moon J, Lee H, Kim J . Anti-fibrotic effect of chorionic plate-derived mesenchymal stem cells isolated from human placenta in a rat model of CCl(4)-injured liver: potential application to the treatment of hepatic diseases. J Cell Biochem. 2010; 111(6):1453-63. DOI: 10.1002/jcb.22873. View

Honardoust D, Ding J, Varkey M, Shankowsky H, Tredget E . Deep dermal fibroblasts refractory to migration and decorin-induced apoptosis contribute to hypertrophic scarring. J Burn Care Res. 2012; 33(5):668-77. DOI: 10.1097/BCR.0b013e31824088e3. View

10.

Tuan T, Nichter L . The molecular basis of keloid and hypertrophic scar formation. Mol Med Today. 1998; 4(1):19-24. DOI: 10.1016/S1357-4310(97)80541-2. View

11.

Mukhopadhyay A, Wong M, Chan S, Do D, Khoo A, Ong C . Syndecan-2 and decorin: proteoglycans with a difference--implications in keloid pathogenesis. J Trauma. 2010; 68(4):999-1008. DOI: 10.1097/TA.0b013e3181c4070d. View

12.

Le A, Zhang Q, Wu Y, Messadi D, Akhondzadeh A, Nguyen A . Elevated vascular endothelial growth factor in keloids: relevance to tissue fibrosis. Cells Tissues Organs. 2004; 176(1-3):87-94. DOI: 10.1159/000075030. View

13.

Tsai P, Fu T, Chen Y, Ko T, Chen T, Shih Y . The therapeutic potential of human umbilical mesenchymal stem cells from Wharton's jelly in the treatment of rat liver fibrosis. Liver Transpl. 2009; 15(5):484-95. DOI: 10.1002/lt.21715. View

14.

Arno A, Smith A, Blit P, Shehab M, Gauglitz G, Jeschke M . Stem Cell Therapy: A New Treatment for Burns?. Pharmaceuticals (Basel). 2016; 4(10):1355-1380. PMC: 4060129. DOI: 10.3390/ph4101355. View

15.

Steinbrech D, Mehrara B, Chau D, Rowe N, Chin G, Lee T . Hypoxia upregulates VEGF production in keloid fibroblasts. Ann Plast Surg. 1999; 42(5):514-9; discussion 519-20. DOI: 10.1097/00000637-199905000-00009. View

16.

Bongso A, Fong C . The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton's jelly of the human umbilical cord. Stem Cell Rev Rep. 2012; 9(2):226-40. DOI: 10.1007/s12015-012-9418-z. View

17.

Shih B, Garside E, McGrouther D, Bayat A . Molecular dissection of abnormal wound healing processes resulting in keloid disease. Wound Repair Regen. 2009; 18(2):139-53. DOI: 10.1111/j.1524-475X.2009.00553.x. View

18.

Wu H, Wang S, Xue A, Liu Y, Liu Y, Wang H . Overexpression of decorin induces apoptosis and cell growth arrest in cultured rat mesangial cells in vitro. Nephrology (Carlton). 2008; 13(7):607-15. DOI: 10.1111/j.1440-1797.2008.00961.x. View

19.

Meenakshi J, Vidyameenakshi S, Ananthram D, Ramakrishnan K, Jayaraman V, Babu M . Low decorin expression along with inherent activation of ERK1,2 in ear lobe keloids. Burns. 2009; 35(4):519-26. DOI: 10.1016/j.burns.2008.07.012. View

20.

Iqbal S, Sidgwick G, Bayat A . Identification of fibrocytes from mesenchymal stem cells in keloid tissue: a potential source of abnormal fibroblasts in keloid scarring. Arch Dermatol Res. 2012; 304(8):665-71. DOI: 10.1007/s00403-012-1225-5. View